Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,655Revenue (TTM) $M134Net Margin (%)-86.8Altman Z-Score-0.2
Enterprise Value $M1,691EPS (TTM) $-0.9Operating Margin %-70.7Piotroski F-Score2
P/E(ttm)--Beneish M-Score-4.8Pre-tax Margin (%)-85.8Higher ROA y-yN
Price/Book--10-y EBITDA Growth Rate %1.4Quick Ratio3.4Cash flow > EarningsY
Price/Sales12.25-y EBITDA Growth Rate %9.6Current Ratio3.6Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-42.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M130ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with HALO

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

HALO is held by these investors:



HALO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-25.81view
Stelzer LaurieCFO 2015-08-20Buy10,000$17.24-25.81view
Kelley Kenneth JDirector 2015-06-18Sell20,000$21-39.1view
Kelley Kenneth JDirector 2015-03-05Sell40,000$15.33-16.57view
RAMSAY DAVID AVP and CFO 2014-09-16Buy25,000$8.943.71view
Torley HelenPresident and CEO 2014-09-16Buy50,000$8.9243.39view
PATTON JOHN STUARTDirector 2014-08-19Sell75,000$9.9628.41view
Engler RobertDirector 2014-08-14Sell35,000$9.9628.41view
Engler RobertDirector 2014-05-15Sell126,700$7.5669.18view
PATTON JOHN STUARTDirector 2013-09-16Sell75,000$9.1340.09view

Quarterly/Annual Reports about HALO:

News about HALO:

Articles On GuruFocus.com
Halozyme Reports First Quarter 2017 Financial Results May 09 2017 
Halozyme To Host First Quarter 2017 Financial Results Conference Call Apr 10 2017 
Halozyme's PEGPH20 Increases Immune Response and Effectiveness of Immunotherapies in Preclinical Can Apr 03 2017 
FDA Advisory Committee Provides Unanimous Recommendation For Subcutaneous Rituximab Coformulated Wit Mar 31 2017 
Halozyme Provides Update On SWOG Collaborative Group Clinical Study Mar 31 2017 
Abbvie Ends Development Program With Halozyme Nov 21 2016 
First Eagle Fund of America 3rd Quarter Commentary Oct 28 2016 
First Eagle Overseas Fund Q2 Commentary Aug 03 2015 
Insider Buys at Halozyme Look to Improve Stock Outlook Sep 18 2014 
Halozyme Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 

More From Other Websites
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : May... May 22 2017
Why Halozyme Therapeutics, Seadrill, and Sibanye Gold Slumped Today May 19 2017
Halozyme Therapeutics, Inc.'s Necessary Move Sends Shares Down as Much as 10% May 19 2017
Biotech Movers: Lion Biotechnologies, XBiotech, Halozyme May 19 2017
Halozyme Therapeutics Prices Public Offering Of Common Stock May 18 2017
Halozyme shares fall after secondary share offering annoucned May 18 2017
Halozyme Therapeutics Announces Public Offering Of Common Stock May 18 2017
Blog Coverage: Omeros' Stock Jumped on Completion of IgA nephropathy Cohort and Additional Positive... May 18 2017
Halozyme Phase 2 Data In Advanced Pancreas Cancer To Be Featured In An Oral Presentation At ASCO May 17 2017
Edited Transcript of HALO earnings conference call or presentation 9-May-17 8:30pm GMT May 15 2017
Halozyme Therapeutics reports 1Q loss May 09 2017
Halozyme Reports First Quarter 2017 Financial Results May 09 2017
Investor Network: Halozyme Therapeutics, Inc. to Host Earnings Call May 09 2017
Halozyme Therapeutics, Inc. – Value Analysis (NASDAQ:HALO) : April 24, 2017 Apr 24 2017
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : HALO-US : April... Apr 21 2017
If You Don't Buy These 5 Stocks Before Their Looming Breakout, It's Your Loss Apr 20 2017
Halozyme To Host First Quarter 2017 Financial Results Conference Call Apr 10 2017
Halozyme Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : HALO-US : April... Apr 06 2017
Halozyme's PEGPH20 Increases Immune Response and Effectiveness of Immunotherapies in Preclinical... Apr 03 2017
Rosetta Genomics and Halozyme Therapeutics: Wait for Better News Mar 31 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat